Verrica Pharmaceuticals

Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, is led by a team of highly experienced individuals focused on the development and commercialization of dermatological treatments. The company is dedicated to redefining dermatology by bringing innovative drugs to market, improving delivery methods, and maintaining frequent engagement with healthcare providers. Verrica's late-stage candidate product, VP-102, is under development for the treatment of molluscum contagiosum, common warts, and external genital warts—three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based candidate product, for the treatment of plantar warts. Additionally, the company has entered into a global licensing agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for conditions in skin oncology.